Edition:
United Kingdom

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

18.86USD
9:00pm BST
Change (% chg)

$-0.68 (-3.48%)
Prev Close
$19.54
Open
$19.31
Day's High
$19.48
Day's Low
$18.63
Volume
245,420
Avg. Vol
502,203
52-wk High
$23.50
52-wk Low
$5.47

Chart for

About

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved... (more)

Overall

Beta: 1.56
Market Cap(Mil.): $1,341.42
Shares Outstanding(Mil.): 93.94
Dividend: --
Yield (%): --

Financials

  SPPI.OQ Industry Sector
P/E (TTM): -- 84.02 32.74
EPS (TTM): -0.99 -- --
ROI: -22.34 1.58 14.38
ROE: -36.04 2.41 16.07

BRIEF-Shrotriya May Sell Up To 1 Mln Shares Of Spectrum Pharmaceuticals' Common Stock

* RAJESH C. SHROTRIYA - SHROTRIYA MAY SELL UP TO 1 MILLION SHARES OF SPECTRUM PHARMACEUTICALS' COMMON STOCK BETWEEN MARCH 26 AND JUNE 29 - SEC FILING‍​ Source text: (https://bit.ly/2pKokJc) Further company coverage:

27 Mar 2018

BRIEF-Spectrum Pharma Q4 Loss Per Share $0.29

* SPECTRUM PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS AND PIPELINE UPDATE

06 Mar 2018

BRIEF-Spectrum Pharmaceuticals Announces Appointment Of William Ashton To Its Board

* SPECTRUM PHARMACEUTICALS ANNOUNCES APPOINTMENT OF WILLIAM L. ASHTON TO ITS BOARD OF DIRECTORS

27 Feb 2018

BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study

* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTIS™ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY

05 Feb 2018

BRIEF-Spectrum Pharmaceuticals Says Expect To File A Registration Application (Bla) With FDA For Rolontis

* SPECTRUM PHARMACEUTICALS SAYS EXPECT TO FILE A REGISTRATION APPLICATION (BLA) WITH FDA FOR ROLONTIS IN Q4 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2EmWf09) Further company coverage:

08 Jan 2018

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

02 Nov 2017

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

30 Oct 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $127.55 -0.17
Pfizer Inc. (PFE.N) $36.53 +0.04
Novartis AG (NOVN.S) CHF77.28 -1.52
Merck & Co., Inc. (MRK.N) $58.64 -0.28
Roche Holding Ltd. (ROG.S) CHF216.50 -0.05
Roche Holding Ltd. (RO.S) CHF220.20 -0.80
Abbott Laboratories (ABT.N) $59.88 +0.36
Bayer AG (BAYGn.DE) €99.60 -0.70
Bayer AG (BAYE.F) -- --
Sanofi SA (SASY.PA) €65.60 -0.21

Earnings vs. Estimates